Conclusion shows that at the end of twelve months, almost all (91.7%) patients which responded to the treatment, maintained success following one year. To note, patients chosen for this study were termed “challenging patients”. The article can be found at http://www.smoa.jsexmed.org/#/article/S2050-1161(16)30042-3/fulltext

About DirexGroup:
DirexGroup specializes in introducing innovative high-technology devices for urologists in all worldwide markets. DirexGroup, established over 30 years ago, has continuously extended its worldwide presence in numerous countries and markets. DirexGroup has put its emphasis on the field of urology and offers urologists and medical centers various equipment and service solutions to their clinical and economic needs. Our products are characterized by reliability, modularity and transportability combined with cost effectiveness and ease of use. A worldwide network of committed service centers assures competent support and maintenance. Contact DirexGroup at: This email address is being protected from spambots. You need JavaScript enabled to view it.